Familial Antiphospholipid Syndrome: A Patient Guide
At a Glance
Familial antiphospholipid syndrome reflects complex inherited susceptibility, not a single predictable gene. Diagnosis requires persistent antibodies plus a clot or pregnancy complication, and treatment is individualized, often using warfarin or heparin with low-dose aspirin during pregnancy.
Familial Antiphospholipid Syndrome (APS) is a rare autoimmune condition where the body’s immune system mistakenly produces antibodies that increase the risk of blood clots and pregnancy complications. While it can cluster in families, it is not a “single-gene” disorder that is passed down in a predictable way. Instead, it is a complex, polygenic condition where several different genes create a baseline of susceptibility [1][2]. Having these genetic markers means your “volume” for an immune reaction is turned up, but it does not guarantee that you will ever develop the disease itself.
The behavior of APS is best understood through the “two-hit” model or hypothesis. The first hit is your genetic foundation—the inherited markers that allow these specific antibodies to exist in your blood. However, these antibodies often circulate harmlessly until a second hit occurs. This second hit is an environmental trigger, such as a major infection, surgery, trauma, or the physical stress of pregnancy, which “activates” the antibodies and causes the blood to clot [3][4]. Keep in mind that triggers and risk factors cannot always be avoided, and a clot is not evidence that you failed to manage stress or lifestyle. Because of this, many people may carry the antibodies (known as being an aPL carrier) for their entire lives without ever experiencing a clinical event.
To ensure an accurate diagnosis, doctors follow a strict rule of persistence along with clinical history. Because antibodies can spike temporarily during a common cold or flu, a laboratory finding of APS requires two positive blood tests taken at least 12 weeks apart [5][6]. This confirms the antibodies are a persistent part of your biology rather than a passing reaction to an infection. A full diagnosis of APS requires these lab results plus a compatible clinical event, like a clot or pregnancy morbidity. Once diagnosed, the focus shifts to long-term protection, which often involves long-term blood-thinning medication depending on individualized factors. Never stop your blood thinner without your prescriber’s direction.
The standard of care for preventing future clots is the use of Vitamin K Antagonists, most commonly Warfarin. While newer “no-test” blood thinners called DOACs are popular for other conditions, they are generally avoided in APS—especially for those with “triple-positive” antibodies or a history of arterial clots—because they have been shown to be less effective at preventing strokes in this specific population [7][8]. For pregnancy, the strategy changes to using Heparin and low-dose aspirin to protect both the parent and the developing placenta [9].
In very rare cases, the syndrome can escalate into an emergency called Catastrophic APS (CAPS), where clots form in multiple organs over a few days. While frightening, this affects fewer than 1% of patients and is managed with intensive hospital care [10][11]. For the vast majority of patients, living with APS means staying vigilant with monitoring, managing heart-health risks like blood pressure, and working closely with a specialist to keep your immune system as stable as possible.
In this guide
7 chapters
Understanding Genetic Risk in Antiphospholipid Syndrome (APS)
Learn how familial antiphospholipid syndrome differs from inherited disease, what aPL antibodies mean, and how to manage clot and pregnancy risks safely.
Recognizing Symptoms and Emergency Warning Signs
Learn to recognize antiphospholipid syndrome symptoms, blood clot warning signs, and catastrophic APS (CAPS) emergencies, including when to seek immediate care.
The Science of APS: Why the 'Two-Hit' Model Matters
Understand familial antiphospholipid syndrome's two-hit model, including genetic susceptibility, environmental triggers, antibodies, and blood-clot risk.
Diagnosis and Deciphering Your Lab Results
Learn how antiphospholipid syndrome testing works, including the three antibodies, 12-week confirmation, blood thinner interference, and risk levels for care.
Treatment Standards for Blood Clots in APS
Learn how blood clots in antiphospholipid syndrome are treated with warfarin, INR monitoring, and emergency plans, including when DOACs may be unsafe.
Pregnancy Planning and Obstetric APS Care
Learn how to plan a pregnancy with antiphospholipid syndrome, including aspirin and heparin choices, antibody risk, monitoring, delivery, and postpartum care.
Long-Term Prevention and Family Health
Learn when relatives of someone with antiphospholipid syndrome need testing, how high-risk carriers prevent clots, and which heart-health checks support safety.
Common questions in this guide
Is familial antiphospholipid syndrome passed down from a parent?
How is antiphospholipid syndrome diagnosed?
What does the two-hit model mean in familial APS?
Is warfarin safer or more effective than a DOAC for APS?
What medicines are used for antiphospholipid syndrome during pregnancy?
What is catastrophic antiphospholipid syndrome, and how common is it?
What should I do if I need surgery or develop a major infection with APS?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my family history and antibody profile, what is my individual risk of a 'second hit' event?
- 2.How does my specific antibody status—single, double, or triple positive—affect the choice of blood thinner?
- 3.If I am currently on a DOAC, should we reconsider switching to Warfarin for better protection?
- 4.What are the specific 'red flag' symptoms I should teach my family members to look for?
- 5.If I have a surgery or a major infection, how will my care change to prevent an APS flare or CAPS?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (11)
- 1
Genetics of Antiphospholipid Syndrome.
Ortiz-Fernández L, Sawalha AH
Current rheumatology reports 2019; (21(12)):65 doi:10.1007/s11926-019-0869-y.
PMID: 31807905 - 2
Genetic aspects of the antiphospholipid syndrome: An update.
Sebastiani GD, Iuliano A, Cantarini L, Galeazzi M
Autoimmunity reviews 2016; (15(5)):433-9.
PMID: 26804759 - 3
Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome.
Yang L, Guo R, Liu H, et al.
Frontiers in immunology 2025; (16()):1527554 doi:10.3389/fimmu.2025.1527554.
PMID: 40181965 - 4
An Update on Antiphospholipid Syndrome.
Xourgia E, Tektonidou MG
Current rheumatology reports 2022; (23(12)):84 doi:10.1007/s11926-021-01051-5.
PMID: 34985625 - 5
Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies.
Tufano A, Di Minno MND, Guida A, et al.
Seminars in thrombosis and hemostasis 2019; (45(5)):468-477 doi:10.1055/s-0039-1692702.
PMID: 31216589 - 6
[Laboratory diagnosis of antiphospholipid syndrome: From criteria to practice].
Joste V, Dragon-Durey MA, Darnige L
La Revue de medecine interne 2018; (39(1)):34-41 doi:10.1016/j.revmed.2017.02.006.
PMID: 28302338 - 7
Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines.
Pastori D, Menichelli D, Cammisotto V, Pignatelli P
Frontiers in cardiovascular medicine 2021; (8()):715878 doi:10.3389/fcvm.2021.715878.
PMID: 34414220 - 8
Antiphospholipid Syndrome: State of the Art of Clinical Management.
Depietri L, Veropalumbo MR, Leone MC, Ghirarduzzi A
Cardiovascular drugs and therapy 2025; (39(2)):385-404 doi:10.1007/s10557-023-07496-3.
PMID: 37572208 - 9
Obstetric antiphospholipid syndrome.
Soto-Peleteiro A, Gonzalez-Echavarri C, Ruiz-Irastorza G
Medicina clinica 2024; (163 Suppl 1()):S14-S21 doi:10.1016/j.medcli.2024.05.001.
PMID: 39174149 - 10
Antiphospholipid Patients Admitted in the Intensive Care Unit: What Must The Rheumatologist Know?
Moyon Q, Mathian A, Papo M, et al.
Current rheumatology reports 2024; (26(7)):269-277 doi:10.1007/s11926-024-01148-7.
PMID: 38652403 - 11
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease.
Salter BM, Crowther MA
Hematology. American Society of Hematology. Education Program 2024; (2024(1)):214-221 doi:10.1182/hematology.2024000544.
PMID: 39644034
This page is for informational purposes only and does not constitute medical advice. Discuss antibody testing, blood thinners, pregnancy care, and surgery planning with your healthcare team.
Get notified when new evidence is published on familial antiphospholipid syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.